With thousands of medical studies published every day, it’s impossible to cover even 1 percent of them. When you can only choose a tiny fraction of studies to cover — particularly if you freelance or your editor gives you some autonomy and flexibility in this area — how do you decide whether or not to cover a study?
Reasons can vary: Some people focus on the better known “more prestigious” journals, although that approach has its drawbacks. Continue reading
As we cover leadership changes at the federal Centers for Medicare and Medicaid Services (CMS), it is worth reflecting on the advancements at the federal agency in recent years – especially its increased focus on health information technology.
The CMS oversees the Medicare and Medicaid programs, but its duties expanded over the past decade to include greater access to health information online, and to spurring technology innovation in the health sector.
Technology was a focus of outgoing Acting Administrator Andy Slavitt’s prepared final remarks to the CMS staff, delivered Thursday morning. Continue reading
AHCJ’s board of directors has voted unanimously to add a new item to its Statement of Principles, the association’s compendium of professional and ethical guidelines.
These principles lie at the core of AHCJ’s mission to promote the highest standards of health care journalism, and have been little changed since the organization was founded.
Adding a new principle is a significant move that may prove especially relevant in the years ahead. Continue reading
The Food and Drug Administration has banned a communications practice that troubled journalists and sparked protests from AHCJ and others.
The agency has forbidden its media staff from using “close-hold embargoes,” in which reporters receive early access to information provided they promise not to seek comments from others until the embargo lifts, according to a letter sent Thursday to Karl Stark, president of the Association of Health Care Journalists. Continue reading
The potential benefits of genetic testing are widely touted and drive greater interest in these tests – even though the validity of the science behind such testing remains unclear.
Charles Piller, the West Coast editor for Boston-based online news site Stat, recently reported on the lack of a firm scientific basis for a test that Proove Biosciences in Irvine, Calif., has been marketing as an “opioid risk” detector. Continue reading